Patterns of medical practice in cystic fibrosis: Part II. Use of therapies

Michael W. Konstan, Steven M. Butler, Daniel V. Schidlow, Wayne J Morgan, Joanne R. Julius, Charles A. Johnson

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

This report describes the prescribing pattern of therapeutic interventions in the management of patients with cystic fibrosis (CF), as observed in the Epidemiologic Study of Cystic Fibrosis (ESCF). Use of 20 therapies by 12,622 patients was recorded from each health care encounter (53,024 outpatient visits and 8,561 hospitalizations) during a 1-year period (1995), and analyzed by gender, age, severity of lung disease, and presence of any Pseudomonas species in the respiratory tract. The percentage of patients using the following pulmonary therapies was observed (in descending order): airway clearance techniques (88.2%); inhaled bronchodilators (82.2%); oral antibiotics (excluding quinolones) (68.2%); dornase alfa (52.9%); intravenous antibiotics (34.4%); oral quinolones (34.4%); inhaled antibiotics (34.3%); mast cell stabilizers (29.5%); inhaled corticosteroids (25.9%); oral corticosteroids (17.1%); oral bronchodilators (16.2%); oxygen (8.1%); inhaled mucolytic agent acetyl cysteine (6.5%); and diuretics (1.4%). The percentage of patients using nutritional therapies was: pancreatic enzymes (96%); oral nutritional supplements (31.1%); enteral nutrition (7.3%); and parenteral nutrition (0.7%). The percentage of patients using other therapies was: nonsteroidal anti-inflammatory drugs (7.9%); and insulin or oral hypoglycemic agents (6.1%). The general trend was for therapies to be used more by older patients, those with lower pulmonary function, and by those with Pseudomonas in their respiratory tract. Exceptions to this trend occurred for airway clearance, oral antibiotics, mast cell stabilizers, and pancreatic enzymes. Four therapies (oral nutritional supplements, parenteral nutrition, diuretics, and pancreatic enzymes) were used more by males than females. However, there was no gender difference for this group of therapies on pulmonary or nutritional status.

Original languageEnglish (US)
Pages (from-to)248-254
Number of pages7
JournalPediatric Pulmonology
Volume28
Issue number4
DOIs
StatePublished - Oct 1999

Fingerprint

Cystic Fibrosis
Anti-Bacterial Agents
Bronchodilator Agents
Quinolones
Parenteral Nutrition
Pseudomonas
Diuretics
Mast Cells
Respiratory System
Lung
Therapeutics
Adrenal Cortex Hormones
Enzymes
Expectorants
Enteral Nutrition
Group Psychotherapy
Nutritional Status
Hypoglycemic Agents
Lung Diseases
Cysteine

Keywords

  • Airway clearance
  • Anti-inflammatory agents
  • Antibiotic
  • Bronchodilator
  • Children
  • Corticosteroid
  • Cystic fibrosis
  • Dornase alfa
  • Nutritional supplement
  • Pancreatic enzyme
  • Treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pulmonary and Respiratory Medicine

Cite this

Patterns of medical practice in cystic fibrosis : Part II. Use of therapies. / Konstan, Michael W.; Butler, Steven M.; Schidlow, Daniel V.; Morgan, Wayne J; Julius, Joanne R.; Johnson, Charles A.

In: Pediatric Pulmonology, Vol. 28, No. 4, 10.1999, p. 248-254.

Research output: Contribution to journalArticle

Konstan, Michael W. ; Butler, Steven M. ; Schidlow, Daniel V. ; Morgan, Wayne J ; Julius, Joanne R. ; Johnson, Charles A. / Patterns of medical practice in cystic fibrosis : Part II. Use of therapies. In: Pediatric Pulmonology. 1999 ; Vol. 28, No. 4. pp. 248-254.
@article{ef041381cf2d441e9aaf0e1e40a1576a,
title = "Patterns of medical practice in cystic fibrosis: Part II. Use of therapies",
abstract = "This report describes the prescribing pattern of therapeutic interventions in the management of patients with cystic fibrosis (CF), as observed in the Epidemiologic Study of Cystic Fibrosis (ESCF). Use of 20 therapies by 12,622 patients was recorded from each health care encounter (53,024 outpatient visits and 8,561 hospitalizations) during a 1-year period (1995), and analyzed by gender, age, severity of lung disease, and presence of any Pseudomonas species in the respiratory tract. The percentage of patients using the following pulmonary therapies was observed (in descending order): airway clearance techniques (88.2{\%}); inhaled bronchodilators (82.2{\%}); oral antibiotics (excluding quinolones) (68.2{\%}); dornase alfa (52.9{\%}); intravenous antibiotics (34.4{\%}); oral quinolones (34.4{\%}); inhaled antibiotics (34.3{\%}); mast cell stabilizers (29.5{\%}); inhaled corticosteroids (25.9{\%}); oral corticosteroids (17.1{\%}); oral bronchodilators (16.2{\%}); oxygen (8.1{\%}); inhaled mucolytic agent acetyl cysteine (6.5{\%}); and diuretics (1.4{\%}). The percentage of patients using nutritional therapies was: pancreatic enzymes (96{\%}); oral nutritional supplements (31.1{\%}); enteral nutrition (7.3{\%}); and parenteral nutrition (0.7{\%}). The percentage of patients using other therapies was: nonsteroidal anti-inflammatory drugs (7.9{\%}); and insulin or oral hypoglycemic agents (6.1{\%}). The general trend was for therapies to be used more by older patients, those with lower pulmonary function, and by those with Pseudomonas in their respiratory tract. Exceptions to this trend occurred for airway clearance, oral antibiotics, mast cell stabilizers, and pancreatic enzymes. Four therapies (oral nutritional supplements, parenteral nutrition, diuretics, and pancreatic enzymes) were used more by males than females. However, there was no gender difference for this group of therapies on pulmonary or nutritional status.",
keywords = "Airway clearance, Anti-inflammatory agents, Antibiotic, Bronchodilator, Children, Corticosteroid, Cystic fibrosis, Dornase alfa, Nutritional supplement, Pancreatic enzyme, Treatment",
author = "Konstan, {Michael W.} and Butler, {Steven M.} and Schidlow, {Daniel V.} and Morgan, {Wayne J} and Julius, {Joanne R.} and Johnson, {Charles A.}",
year = "1999",
month = "10",
doi = "10.1002/(SICI)1099-0496(199910)28:4<248::AID-PPUL3>3.0.CO;2-N",
language = "English (US)",
volume = "28",
pages = "248--254",
journal = "Pediatric Pulmonology",
issn = "8755-6863",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Patterns of medical practice in cystic fibrosis

T2 - Part II. Use of therapies

AU - Konstan, Michael W.

AU - Butler, Steven M.

AU - Schidlow, Daniel V.

AU - Morgan, Wayne J

AU - Julius, Joanne R.

AU - Johnson, Charles A.

PY - 1999/10

Y1 - 1999/10

N2 - This report describes the prescribing pattern of therapeutic interventions in the management of patients with cystic fibrosis (CF), as observed in the Epidemiologic Study of Cystic Fibrosis (ESCF). Use of 20 therapies by 12,622 patients was recorded from each health care encounter (53,024 outpatient visits and 8,561 hospitalizations) during a 1-year period (1995), and analyzed by gender, age, severity of lung disease, and presence of any Pseudomonas species in the respiratory tract. The percentage of patients using the following pulmonary therapies was observed (in descending order): airway clearance techniques (88.2%); inhaled bronchodilators (82.2%); oral antibiotics (excluding quinolones) (68.2%); dornase alfa (52.9%); intravenous antibiotics (34.4%); oral quinolones (34.4%); inhaled antibiotics (34.3%); mast cell stabilizers (29.5%); inhaled corticosteroids (25.9%); oral corticosteroids (17.1%); oral bronchodilators (16.2%); oxygen (8.1%); inhaled mucolytic agent acetyl cysteine (6.5%); and diuretics (1.4%). The percentage of patients using nutritional therapies was: pancreatic enzymes (96%); oral nutritional supplements (31.1%); enteral nutrition (7.3%); and parenteral nutrition (0.7%). The percentage of patients using other therapies was: nonsteroidal anti-inflammatory drugs (7.9%); and insulin or oral hypoglycemic agents (6.1%). The general trend was for therapies to be used more by older patients, those with lower pulmonary function, and by those with Pseudomonas in their respiratory tract. Exceptions to this trend occurred for airway clearance, oral antibiotics, mast cell stabilizers, and pancreatic enzymes. Four therapies (oral nutritional supplements, parenteral nutrition, diuretics, and pancreatic enzymes) were used more by males than females. However, there was no gender difference for this group of therapies on pulmonary or nutritional status.

AB - This report describes the prescribing pattern of therapeutic interventions in the management of patients with cystic fibrosis (CF), as observed in the Epidemiologic Study of Cystic Fibrosis (ESCF). Use of 20 therapies by 12,622 patients was recorded from each health care encounter (53,024 outpatient visits and 8,561 hospitalizations) during a 1-year period (1995), and analyzed by gender, age, severity of lung disease, and presence of any Pseudomonas species in the respiratory tract. The percentage of patients using the following pulmonary therapies was observed (in descending order): airway clearance techniques (88.2%); inhaled bronchodilators (82.2%); oral antibiotics (excluding quinolones) (68.2%); dornase alfa (52.9%); intravenous antibiotics (34.4%); oral quinolones (34.4%); inhaled antibiotics (34.3%); mast cell stabilizers (29.5%); inhaled corticosteroids (25.9%); oral corticosteroids (17.1%); oral bronchodilators (16.2%); oxygen (8.1%); inhaled mucolytic agent acetyl cysteine (6.5%); and diuretics (1.4%). The percentage of patients using nutritional therapies was: pancreatic enzymes (96%); oral nutritional supplements (31.1%); enteral nutrition (7.3%); and parenteral nutrition (0.7%). The percentage of patients using other therapies was: nonsteroidal anti-inflammatory drugs (7.9%); and insulin or oral hypoglycemic agents (6.1%). The general trend was for therapies to be used more by older patients, those with lower pulmonary function, and by those with Pseudomonas in their respiratory tract. Exceptions to this trend occurred for airway clearance, oral antibiotics, mast cell stabilizers, and pancreatic enzymes. Four therapies (oral nutritional supplements, parenteral nutrition, diuretics, and pancreatic enzymes) were used more by males than females. However, there was no gender difference for this group of therapies on pulmonary or nutritional status.

KW - Airway clearance

KW - Anti-inflammatory agents

KW - Antibiotic

KW - Bronchodilator

KW - Children

KW - Corticosteroid

KW - Cystic fibrosis

KW - Dornase alfa

KW - Nutritional supplement

KW - Pancreatic enzyme

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032869672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032869672&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1099-0496(199910)28:4<248::AID-PPUL3>3.0.CO;2-N

DO - 10.1002/(SICI)1099-0496(199910)28:4<248::AID-PPUL3>3.0.CO;2-N

M3 - Article

C2 - 10497373

AN - SCOPUS:0032869672

VL - 28

SP - 248

EP - 254

JO - Pediatric Pulmonology

JF - Pediatric Pulmonology

SN - 8755-6863

IS - 4

ER -